Immuno-efficacy results from molecular docking analysis successfully predicted the stable interaction between Tretinoin and the corresponding proteins of PDK1, XBP1 and ACACB, indicating their potential as drug targets for RA treatment in terms of abnormal fatty acid metabolism. This evidence concerns the gene ACACB and rheumatoid arthritis.